ID   LGI1_HUMAN              Reviewed;         557 AA.
AC   O95970; A8K0Z1; B4E1S0; Q5W001; Q5W002; Q8NI23; Q96LF5;
DT   03-JUL-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   07-APR-2021, entry version 180.
DE   RecName: Full=Leucine-rich glioma-inactivated protein 1;
DE   AltName: Full=Epitempin-1;
DE   Flags: Precursor;
GN   Name=LGI1; Synonyms=EPT; ORFNames=UNQ775/PRO1569;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=9879993; DOI=10.1038/sj.onc.1202481;
RA   Chernova O.B., Somerville R.P., Cowell J.K.;
RT   "A novel gene, LGI1, from 10q24 is rearranged and downregulated in
RT   malignant brain tumors.";
RL   Oncogene 17:2873-2881(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND DISEASE.
RX   PubMed=11978770; DOI=10.1093/hmg/11.9.1119;
RA   Morante-Redolat J.M., Gorostidi-Pagola A., Piquer-Sirerol S., Saenz A.,
RA   Poza J.J., Galan J., Gesk S., Sarafidou T., Mautner V.F., Binelli S.,
RA   Staub E., Hinzmann B., French L., Prud'homme J.-F., Passarelli D.,
RA   Scannapieco P., Tassinari C.A., Avanzini G., Marti-Masso J.F., Kluwe L.,
RA   Deloukas P., Moschonas N.K., Michelucci R., Siebert R., Nobile C.,
RA   Perez-Tur J., Lopez de Munain A.;
RT   "Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant
RT   lateral temporal epilepsy.";
RL   Hum. Mol. Genet. 11:1119-1128(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Brain, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION.
RX   PubMed=15047712; DOI=10.1074/jbc.m314192200;
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RT   "LGI1, a putative tumor metastasis suppressor gene, controls in vitro
RT   invasiveness and expression of matrix metalloproteinases in glioma cells
RT   through the ERK1/2 pathway.";
RL   J. Biol. Chem. 279:23151-23157(2004).
RN   [9]
RP   ERRATUM OF PUBMED:15047712.
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RL   J. Biol. Chem. 282:2752-2752(2007).
RN   [10]
RP   SUBCELLULAR LOCATION, GLYCOSYLATION, MUTAGENESIS OF ASN-192; ASN-277 AND
RP   ASN-422, AND CHARACTERIZATION OF VARIANTS ETL1 ARG-46; ARG-145; ARG-200;
RP   CYS-318 AND ALA-383.
RX   PubMed=17067999; DOI=10.1093/hmg/ddl421;
RA   Sirerol-Piquer M.S., Ayerdi-Izquierdo A., Morante-Redolat J.M.,
RA   Herranz-Perez V., Favell K., Barker P.A., Perez-Tur J.;
RT   "The epilepsy gene LGI1 encodes a secreted glycoprotein that binds to the
RT   cell surface.";
RL   Hum. Mol. Genet. 15:3436-3445(2006).
RN   [11]
RP   FUNCTION, INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16518856; DOI=10.1002/jcp.20627;
RA   Gabellini N., Masola V., Quartesan S., Oselladore B., Nobile C.,
RA   Michelucci R., Curtarello M., Parolin C., Palu G.;
RT   "Increased expression of LGI1 gene triggers growth inhibition and apoptosis
RT   of neuroblastoma cells.";
RL   J. Cell. Physiol. 207:711-721(2006).
RN   [12]
RP   SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=16787412; DOI=10.1111/j.1471-4159.2006.03939.x;
RA   Furlan S., Roncaroli F., Forner F., Vitiello L., Calabria E.,
RA   Piquer-Sirerol S., Valle G., Perez-Tur J., Michelucci R., Nobile C.;
RT   "The LGI1/epitempin gene encodes two protein isoforms differentially
RT   expressed in human brain.";
RL   J. Neurochem. 98:985-991(2006).
RN   [13]
RP   SUBCELLULAR LOCATION, VARIANT ETL1 PRO-232, AND CHARACTERIZATION OF
RP   VARIANTS ETL1 PRO-232 AND ALA-383.
RX   PubMed=17296837; DOI=10.1001/archneur.64.2.217;
RA   Chabrol E., Popescu C., Gourfinkel-An I., Trouillard O., Depienne C.,
RA   Senechal K., Baulac M., LeGuern E., Baulac S.;
RT   "Two novel epilepsy-linked mutations leading to a loss of function of
RT   LGI1.";
RL   Arch. Neurol. 64:217-222(2007).
RN   [14]
RP   REVIEW ON VARIANTS.
RX   PubMed=19191227; DOI=10.1002/humu.20925;
RA   Nobile C., Michelucci R., Andreazza S., Pasini E., Tosatto S.C.,
RA   Striano P.;
RT   "LGI1 mutations in autosomal dominant and sporadic lateral temporal
RT   epilepsy.";
RL   Hum. Mutat. 30:530-536(2009).
RN   [15]
RP   INTERACTION WITH ADAM22.
RX   PubMed=27066583; DOI=10.1212/nxg.0000000000000046;
RA   Muona M., Fukata Y., Anttonen A.K., Laari A., Palotie A., Pihko H.,
RA   Loennqvist T., Valanne L., Somer M., Fukata M., Lehesjoki A.E.;
RT   "Dysfunctional ADAM22 implicated in progressive encephalopathy with
RT   cortical atrophy and epilepsy.";
RL   Neurol. Genet. 2:E46-E46(2016).
RN   [16]
RP   VARIANT ETL1 ALA-383.
RX   PubMed=11810107; DOI=10.1038/ng832;
RA   Kalachikov S., Evgrafov O., Ross B., Winawer M., Barker-Cummings C.,
RA   Boneschi F.M., Choi C., Morozov P., Das K., Teplitskaya E., Yu A.,
RA   Cayanis E., Penchaszadeh G., Kottmann A.H., Pedley T.A., Hauser W.A.,
RA   Ottman R., Gilliam T.C.;
RT   "Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory
RT   features.";
RL   Nat. Genet. 30:335-341(2002).
RN   [17]
RP   VARIANT ETL1 ARG-46.
RX   PubMed=12205652; DOI=10.1002/ana.10280;
RA   Gu W., Brodtkorb E., Steinlein O.K.;
RT   "LGI1 is mutated in familial temporal lobe epilepsy characterized by
RT   aphasic seizures.";
RL   Ann. Neurol. 52:364-367(2002).
RN   [18]
RP   VARIANT ETL1 ARG-26.
RX   PubMed=12601709; DOI=10.1002/ana.10492;
RA   Pizzuti A., Flex E., Di Bonaventura C., Dottorini T., Egeo G., Manfredi M.,
RA   Dallapiccola B., Giallonardo A.T.;
RT   "Epilepsy with auditory features: a LGI1 gene mutation suggests a loss-of-
RT   function mechanism.";
RL   Ann. Neurol. 53:396-399(2003).
RN   [19]
RP   VARIANT ETL1 CYS-318.
RX   PubMed=12771268; DOI=10.1212/01.wnl.0000063324.39980.4a;
RA   Fertig E., Lincoln A., Martinuzzi A., Mattson R.H., Hisama F.M.;
RT   "Novel LGI1 mutation in a family with autosomal dominant partial epilepsy
RT   with auditory features.";
RL   Neurology 60:1687-1690(2003).
RN   [20]
RP   VARIANTS ETL1 GLY-42 AND LEU-473.
RX   PubMed=15079010; DOI=10.1212/01.wnl.0000118213.94650.81;
RA   Berkovic S.F., Izzillo P., McMahon J.M., Harkin L.A., McIntosh A.M.,
RA   Phillips H.A., Briellmann R.S., Wallace R.H., Mazarib A., Neufeld M.Y.,
RA   Korczyn A.D., Scheffer I.E., Mulley J.C.;
RT   "LGI1 mutations in temporal lobe epilepsies.";
RL   Neurology 62:1115-1119(2004).
RN   [21]
RP   VARIANT ETL1 TRP-136.
RX   PubMed=17562837; DOI=10.1212/01.wnl.0000264932.44153.3c;
RA   Michelucci R., Mecarelli O., Bovo G., Bisulli F., Testoni S., Striano P.,
RA   Striano S., Tinuper P., Nobile C.;
RT   "A de novo LGI1 mutation causing idiopathic partial epilepsy with
RT   telephone-induced seizures.";
RL   Neurology 68:2150-2151(2007).
RN   [22]
RP   VARIANT ETL1 LYS-122.
RX   PubMed=18625862; DOI=10.1001/archneur.65.7.939;
RA   Striano P., de Falco A., Diani E., Bovo G., Furlan S., Vitiello L.,
RA   Pinardi F., Striano S., Michelucci R., de Falco F.A., Nobile C.;
RT   "A novel loss-of-function LGI1 mutation linked to autosomal dominant
RT   lateral temporal epilepsy.";
RL   Arch. Neurol. 65:939-942(2008).
RN   [23]
RP   VARIANT ETL1 LYS-123.
RX   PubMed=19552651; DOI=10.1111/j.1528-1167.2009.02181.x;
RA   Bonaventura C.D., Carni M., Diani E., Fattouch J., Vaudano E.A., Egeo G.,
RA   Pantano P., Maraviglia B., Bozzao L., Manfredi M., Prencipe M.,
RA   Giallonardo T.A., Nobile C.;
RT   "Drug resistant ADLTE and recurrent partial status epilepticus with
RT   dysphasic features in a family with a novel LGI1mutation: electroclinical,
RT   genetic, and EEG/fMRI findings.";
RL   Epilepsia 50:2481-2486(2009).
CC   -!- FUNCTION: Regulates voltage-gated potassium channels assembled from
CC       KCNA1, KCNA4 and KCNAB1. It slows down channel inactivation by
CC       precluding channel closure mediated by the KCNAB1 subunit. Ligand for
CC       ADAM22 that positively regulates synaptic transmission mediated by
CC       AMPA-type glutamate receptors (By similarity). Plays a role in
CC       suppressing the production of MMP1/3 through the phosphatidylinositol
CC       3-kinase/ERK pathway. May play a role in the control of neuroblastoma
CC       cell survival. {ECO:0000250, ECO:0000269|PubMed:15047712,
CC       ECO:0000269|PubMed:16518856}.
CC   -!- SUBUNIT: Oligomer. Interacts with KCNA1 within a complex containing
CC       KCNA1, KCNA4 and KCNAB1. Part of a complex containing ADAM22,
CC       DLG4/PSD95 and CACNG2/Stargazin (PubMed:27066583). Can bind to ADAM11
CC       and ADAM23. {ECO:0000250, ECO:0000269|PubMed:27066583}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:16787412,
CC       ECO:0000269|PubMed:17067999, ECO:0000269|PubMed:17296837}. Cell
CC       junction, synapse {ECO:0000250}. Note=Isoform 1 but not isoform 2 is
CC       secreted. Isoform 1 is enriched in the Golgi apparatus while isoform 2
CC       accumulates in the endoplasmic reticulum.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O95970-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O95970-2; Sequence=VSP_007678, VSP_007679;
CC       Name=3;
CC         IsoId=O95970-3; Sequence=VSP_038234;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in neural tissues,
CC       especially in brain. Expression is reduced in low-grade brain tumors
CC       and significantly reduced or absent in malignant gliomas. Isoform 1 is
CC       absent in the cerebellum and is detectable in the occipital cortex and
CC       hippocampus; higher amounts are observed in the parietal and frontal
CC       cortices, putamen, and, particularly, in the temporal neocortex, where
CC       it is 3.5 times more abundant than in the hippocampus (at protein
CC       level). Isoform 3 shows the highest expression in the occipital cortex
CC       and the lowest in the hippocampus (at protein level).
CC       {ECO:0000269|PubMed:16518856, ECO:0000269|PubMed:16787412}.
CC   -!- INDUCTION: Down-regulated in neuroblastoma cells.
CC       {ECO:0000269|PubMed:16518856}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:17067999}.
CC   -!- DISEASE: Epilepsy, familial temporal lobe, 1 (ETL1) [MIM:600512]: A
CC       focal form of epilepsy characterized by recurrent seizures that arise
CC       from foci within the temporal lobe. Seizures are usually accompanied by
CC       sensory symptoms, most often auditory in nature.
CC       {ECO:0000269|PubMed:11810107, ECO:0000269|PubMed:12205652,
CC       ECO:0000269|PubMed:12601709, ECO:0000269|PubMed:12771268,
CC       ECO:0000269|PubMed:15079010, ECO:0000269|PubMed:17067999,
CC       ECO:0000269|PubMed:17296837, ECO:0000269|PubMed:17562837,
CC       ECO:0000269|PubMed:18625862, ECO:0000269|PubMed:19552651}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LGI1ID311ch10q23.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF055636; AAC99316.1; -; mRNA.
DR   EMBL; AF473548; AAM22074.1; -; mRNA.
DR   EMBL; AY358885; AAQ89244.1; -; mRNA.
DR   EMBL; AK289706; BAF82395.1; -; mRNA.
DR   EMBL; AK303956; BAG64882.1; -; mRNA.
DR   EMBL; AL157396; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL358154; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW50052.1; -; Genomic_DNA.
DR   EMBL; BC022500; AAH22500.1; -; mRNA.
DR   CCDS; CCDS7431.1; -. [O95970-1]
DR   CCDS; CCDS76325.1; -. [O95970-2]
DR   CCDS; CCDS81490.1; -. [O95970-3]
DR   RefSeq; NP_001295204.1; NM_001308275.1. [O95970-2]
DR   RefSeq; NP_001295205.1; NM_001308276.1. [O95970-3]
DR   RefSeq; NP_005088.1; NM_005097.3. [O95970-1]
DR   PDB; 5Y2Z; X-ray; 2.67 A; B/D/F/H/J/L=224-557.
DR   PDB; 5Y30; X-ray; 1.78 A; A=37-223.
DR   PDB; 5Y31; X-ray; 7.12 A; B/D=37-557.
DR   PDBsum; 5Y2Z; -.
DR   PDBsum; 5Y30; -.
DR   PDBsum; 5Y31; -.
DR   SMR; O95970; -.
DR   BioGRID; 114645; 2.
DR   CORUM; O95970; -.
DR   STRING; 9606.ENSP00000360472; -.
DR   GlyGen; O95970; 4 sites.
DR   iPTMnet; O95970; -.
DR   PhosphoSitePlus; O95970; -.
DR   BioMuta; LGI1; -.
DR   EPD; O95970; -.
DR   jPOST; O95970; -.
DR   MassIVE; O95970; -.
DR   PaxDb; O95970; -.
DR   PeptideAtlas; O95970; -.
DR   PRIDE; O95970; -.
DR   ProteomicsDB; 51151; -. [O95970-1]
DR   ProteomicsDB; 51152; -. [O95970-2]
DR   ProteomicsDB; 51153; -. [O95970-3]
DR   TopDownProteomics; O95970-3; -. [O95970-3]
DR   ABCD; O95970; 1 sequenced antibody.
DR   Antibodypedia; 30497; 269 antibodies.
DR   DNASU; 9211; -.
DR   Ensembl; ENST00000371413; ENSP00000360467; ENSG00000108231. [O95970-2]
DR   Ensembl; ENST00000371418; ENSP00000360472; ENSG00000108231. [O95970-1]
DR   Ensembl; ENST00000630047; ENSP00000485917; ENSG00000108231. [O95970-3]
DR   GeneID; 9211; -.
DR   KEGG; hsa:9211; -.
DR   UCSC; uc001kjc.5; human. [O95970-1]
DR   CTD; 9211; -.
DR   DisGeNET; 9211; -.
DR   GeneCards; LGI1; -.
DR   GeneReviews; LGI1; -.
DR   HGNC; HGNC:6572; LGI1.
DR   HPA; ENSG00000108231; Tissue enriched (brain).
DR   MalaCards; LGI1; -.
DR   MIM; 600512; phenotype.
DR   MIM; 604619; gene.
DR   neXtProt; NX_O95970; -.
DR   OpenTargets; ENSG00000108231; -.
DR   Orphanet; 101046; Autosomal dominant epilepsy with auditory features.
DR   PharmGKB; PA30349; -.
DR   VEuPathDB; HostDB:ENSG00000108231.11; -.
DR   eggNOG; ENOG502REXX; Eukaryota.
DR   GeneTree; ENSGT00940000159793; -.
DR   HOGENOM; CLU_956325_0_0_1; -.
DR   InParanoid; O95970; -.
DR   OMA; VEWLDHT; -.
DR   PhylomeDB; O95970; -.
DR   TreeFam; TF333155; -.
DR   PathwayCommons; O95970; -.
DR   Reactome; R-HSA-5682910; LGI-ADAM interactions.
DR   BioGRID-ORCS; 9211; 42 hits in 983 CRISPR screens.
DR   ChiTaRS; LGI1; human.
DR   GeneWiki; LGI1; -.
DR   GenomeRNAi; 9211; -.
DR   Pharos; O95970; Tbio.
DR   PRO; PR:O95970; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; O95970; protein.
DR   Bgee; ENSG00000108231; Expressed in caudate nucleus and 154 other tissues.
DR   ExpressionAtlas; O95970; baseline and differential.
DR   Genevisible; O95970; HS.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0043083; C:synaptic cleft; IEA:Ensembl.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:DFLAT.
DR   GO; GO:0007411; P:axon guidance; IMP:DFLAT.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0031175; P:neuron projection development; IMP:DFLAT.
DR   GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IEA:Ensembl.
DR   GO; GO:0030307; P:positive regulation of cell growth; IMP:DFLAT.
DR   GO; GO:0050806; P:positive regulation of synaptic transmission; ISS:UniProtKB.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR009039; EAR.
DR   InterPro; IPR005492; EPTP.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   Pfam; PF03736; EPTP; 7.
DR   Pfam; PF13855; LRR_8; 1.
DR   SMART; SM00369; LRR_TYP; 3.
DR   SMART; SM00082; LRRCT; 1.
DR   PROSITE; PS50912; EAR; 7.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Disease variant;
KW   Epilepsy; Glycoprotein; Leucine-rich repeat; Reference proteome; Repeat;
KW   Secreted; Signal; Synapse.
FT   SIGNAL          1..34
FT                   /evidence="ECO:0000255"
FT   CHAIN           35..557
FT                   /note="Leucine-rich glioma-inactivated protein 1"
FT                   /id="PRO_0000017705"
FT   DOMAIN          35..72
FT                   /note="LRRNT"
FT   REPEAT          92..113
FT                   /note="LRR 1"
FT   REPEAT          116..137
FT                   /note="LRR 2"
FT   REPEAT          140..161
FT                   /note="LRR 3"
FT   DOMAIN          173..223
FT                   /note="LRRCT"
FT   REPEAT          225..267
FT                   /note="EAR 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00075"
FT   REPEAT          271..313
FT                   /note="EAR 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00075"
FT   REPEAT          317..364
FT                   /note="EAR 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00075"
FT   REPEAT          366..415
FT                   /note="EAR 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00075"
FT   REPEAT          419..462
FT                   /note="EAR 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00075"
FT   REPEAT          464..506
FT                   /note="EAR 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00075"
FT   REPEAT          510..552
FT                   /note="EAR 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00075"
FT   CARBOHYD        192
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        277
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        422
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         96..143
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038234"
FT   VAR_SEQ         280..291
FT                   /note="GTSTVVCKPIVI -> VLREIHRFTNMS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11978770"
FT                   /id="VSP_007678"
FT   VAR_SEQ         292..557
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11978770"
FT                   /id="VSP_007679"
FT   VARIANT         26
FT                   /note="L -> R (in ETL1; probably affects signal sequence
FT                   processing and secretion)"
FT                   /evidence="ECO:0000269|PubMed:12601709"
FT                   /id="VAR_015771"
FT   VARIANT         42
FT                   /note="C -> G (in ETL1; dbSNP:rs797044996)"
FT                   /evidence="ECO:0000269|PubMed:15079010"
FT                   /id="VAR_023008"
FT   VARIANT         42
FT                   /note="C -> R (in ETL1; dbSNP:rs797044996)"
FT                   /id="VAR_058538"
FT   VARIANT         46
FT                   /note="C -> R (in ETL1; loss of protein secretion; does not
FT                   affect glycosylation status of the protein;
FT                   dbSNP:rs104894166)"
FT                   /evidence="ECO:0000269|PubMed:12205652,
FT                   ECO:0000269|PubMed:17067999"
FT                   /id="VAR_015772"
FT   VARIANT         110
FT                   /note="A -> D (in ETL1)"
FT                   /id="VAR_058539"
FT   VARIANT         122
FT                   /note="I -> K (in ETL1; dbSNP:rs119488100)"
FT                   /evidence="ECO:0000269|PubMed:18625862"
FT                   /id="VAR_058540"
FT   VARIANT         123
FT                   /note="E -> K (in ETL1)"
FT                   /evidence="ECO:0000269|PubMed:19552651"
FT                   /id="VAR_058541"
FT   VARIANT         136
FT                   /note="R -> W (in ETL1; dbSNP:rs119488099)"
FT                   /evidence="ECO:0000269|PubMed:17562837"
FT                   /id="VAR_058542"
FT   VARIANT         145
FT                   /note="S -> R (in ETL1; loss of protein secretion; does not
FT                   affect glycosylation status of the protein)"
FT                   /evidence="ECO:0000269|PubMed:17067999"
FT                   /id="VAR_058543"
FT   VARIANT         154
FT                   /note="L -> P (in ETL1)"
FT                   /id="VAR_058544"
FT   VARIANT         200
FT                   /note="C -> R (in ETL1; loss of protein secretion; does not
FT                   affect glycosylation status of the protein)"
FT                   /evidence="ECO:0000269|PubMed:17067999"
FT                   /id="VAR_058545"
FT   VARIANT         232
FT                   /note="L -> P (in ETL1; loss of protein secretion;
FT                   dbSNP:rs104894167)"
FT                   /evidence="ECO:0000269|PubMed:17296837"
FT                   /id="VAR_058546"
FT   VARIANT         298
FT                   /note="I -> T (in ETL1)"
FT                   /id="VAR_058547"
FT   VARIANT         318
FT                   /note="F -> C (in ETL1; loss of protein secretion; protein
FT                   is retained in the endoplasmic reticulum; does not affect
FT                   glycosylation status of the protein; dbSNP:rs28939075)"
FT                   /evidence="ECO:0000269|PubMed:12771268,
FT                   ECO:0000269|PubMed:17067999"
FT                   /id="VAR_015774"
FT   VARIANT         383
FT                   /note="E -> A (in ETL1; loss of protein secretion; protein
FT                   is retained in the endoplasmic reticulum; does not affect
FT                   glycosylation status of the protein; dbSNP:rs28937874)"
FT                   /evidence="ECO:0000269|PubMed:11810107,
FT                   ECO:0000269|PubMed:17067999, ECO:0000269|PubMed:17296837"
FT                   /id="VAR_015773"
FT   VARIANT         432
FT                   /note="V -> E (in ETL1)"
FT                   /id="VAR_058548"
FT   VARIANT         473
FT                   /note="S -> L (in ETL1; dbSNP:rs797044999)"
FT                   /evidence="ECO:0000269|PubMed:15079010"
FT                   /id="VAR_023009"
FT   MUTAGEN         192
FT                   /note="N->Q: Affects glycosylation; when associated with Q-
FT                   277 and Q-422. Loss of protein secretion; when associated
FT                   with Q-277 and Q-422."
FT                   /evidence="ECO:0000269|PubMed:17067999"
FT   MUTAGEN         277
FT                   /note="N->Q: Affects glycosylation; when associated with Q-
FT                   192 and Q-422. Loss of protein secretion; when associated
FT                   with Q-192 and Q-422."
FT                   /evidence="ECO:0000269|PubMed:17067999"
FT   MUTAGEN         422
FT                   /note="N->Q: Affects glycosylation; when associated with Q-
FT                   192 and Q-277. Loss of protein secretion; when associated
FT                   with Q-192 and Q-277."
FT                   /evidence="ECO:0000269|PubMed:17067999"
FT   STRAND          46..48
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   STRAND          50..57
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   STRAND          70..76
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   TURN            84..89
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   STRAND          94..100
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   STRAND          102..106
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   TURN            108..113
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   STRAND          119..124
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   STRAND          126..128
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   TURN            132..137
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   STRAND          143..145
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   TURN            156..161
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   STRAND          167..169
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   HELIX           179..181
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   HELIX           182..190
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   STRAND          193..195
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   HELIX           204..206
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   HELIX           211..213
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   HELIX           216..218
FT                   /evidence="ECO:0007744|PDB:5Y30"
FT   STRAND          225..234
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          239..244
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          247..253
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   TURN            255..257
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          259..266
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   TURN            267..270
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          271..279
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          283..291
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          294..304
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          307..312
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   TURN            313..316
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          317..323
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   TURN            326..328
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          331..340
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          343..350
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          352..355
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          357..362
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          367..374
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          379..387
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          396..403
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          409..414
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   TURN            415..418
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          419..425
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          434..440
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          443..449
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          451..461
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          464..475
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          479..484
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          487..492
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          495..497
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          499..505
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   TURN            506..509
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          510..517
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          520..530
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          533..543
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
FT   STRAND          545..551
FT                   /evidence="ECO:0007744|PDB:5Y2Z"
SQ   SEQUENCE   557 AA;  63818 MW;  890EEDA08D95C854 CRC64;
     MESERSKRMG NACIPLKRIA YFLCLLSALL LTEGKKPAKP KCPAVCTCTK DNALCENARS
     IPRTVPPDVI SLSFVRSGFT EISEGSFLFT PSLQLLLFTS NSFDVISDDA FIGLPHLEYL
     FIENNNIKSI SRHTFRGLKS LIHLSLANNN LQTLPKDIFK GLDSLTNVDL RGNSFNCDCK
     LKWLVEWLGH TNATVEDIYC EGPPEYKKRK INSLSSKDFD CIITEFAKSQ DLPYQSLSID
     TFSYLNDEYV VIAQPFTGKC IFLEWDHVEK TFRNYDNITG TSTVVCKPIV IETQLYVIVA
     QLFGGSHIYK RDSFANKFIK IQDIEILKIR KPNDIETFKI ENNWYFVVAD SSKAGFTTIY
     KWNGNGFYSH QSLHAWYRDT DVEYLEIVRT PQTLRTPHLI LSSSSQRPVI YQWNKATQLF
     TNQTDIPNME DVYAVKHFSV KGDVYICLTR FIGDSKVMKW GGSSFQDIQR MPSRGSMVFQ
     PLQINNYQYA ILGSDYSFTQ VYNWDAEKAK FVKFQELNVQ APRSFTHVSI NKRNFLFASS
     FKGNTQIYKH VIVDLSA
//
